As­traZeneca inks deal with Japan­ese biotech JCR in CNS in­di­ca­tion

3 years ago
Deals
R&D

Sec­ond time’s the charm? Cy­cle­ri­on CEO tries again at buy­ing biotech's as­sets

3 years ago
Deals

FTC or­ders Il­lu­mi­na to di­vest Grail, adding pres­sure amid ac­tivist fight with Ic­ahn

3 years ago
R&D

A note to our ad­ver­tis­ing part­ners: End­points News joins the Fi­nan­cial Times fam­i­ly

3 years ago
Publisher's note

From the founders: End­points is now part of the Fi­nan­cial Times fam­i­ly

3 years ago
Publisher's note

BioN­Tech delves in­to AD­Cs with $170M up­front weeks af­ter Pfiz­er lines up Seagen

3 years ago
Startups
Deals

Take­da pays $5M up­front to li­cense an­ti­bod­ies for celi­ac dis­ease drug de­vel­op­ment

3 years ago
R&D

Vedere Bio II, gene ther­a­py biotech born out of No­var­tis buy­out, clos­es down

3 years ago
People

Whoops: CMS qui­et­ly pares back list of drugs re­quir­ing new re­bates un­der In­fla­tion Re­duc­tion Act

3 years ago
Pharma
Law

Top 15 bio­phar­ma R&D spenders; The re­turn of Big Car­dio; Math­ai Mam­men takes biotech CEO role; Kris­ten Hege’s next ...

3 years ago
Weekly

Af­ter Ako­rn's site clo­sures in the US, al­buterol re­mains in short­age

3 years ago
Pharma
Manufacturing

Saris­sa tight­ens its grip on Amarin as CEO re­signs

3 years ago
People
Pharma

Phar­ma in­dus­try rep­u­ta­tion scores pos­i­tive bump from in­sulin pric­ing news — Har­ris Poll

3 years ago
Pharma
Marketing

US gov­ern­ment to SCO­TUS: Take up the Te­va-GSK 'skin­ny' gener­ic drug la­bel case

3 years ago
Pharma
Law

GAO to NIH: Strength­en over­sight of an­i­mal wel­fare for over­seas con­tracts

3 years ago
Pharma

US House as­sem­bles bi­par­ti­san cau­cus on do­mes­tic phar­ma man­u­fac­tur­ing

3 years ago
Pharma
Manufacturing

Cy­to­ki­net­ics’ ALS drug fails PhI­II, leav­ing the biotech with a sin­gle late-stage prospect

3 years ago
R&D

CHMP gives thumbs-up for We­govy use in ado­les­cents, along with nine new drug rec­om­men­da­tions

3 years ago
R&D
FDA+

Green­Light re­ceives buy­out of­fer; Apol­lomics com­pletes SPAC merg­er

3 years ago
News Briefing

TCR up­start an­nounces CEO ex­it, with CSO now act­ing re­place­ment

3 years ago
People

Austin biotech Mol­e­c­u­lar Tem­plates lays off more than 100 staffers as pipeline nar­rows

3 years ago
People
R&D

Aptinyx eval­u­ates fu­ture of the com­pa­ny fol­low­ing two failed tri­als, 60% lay­offs

3 years ago
People
R&D

Sar­to­rius to ac­quire French man­u­fac­tur­er for $2.6B+ in cell and gene ther­a­py play

3 years ago
Deals
Cell/Gene Tx

Jim Mullen scours pri­vate eq­ui­ty deals amid biotech win­ter; Ex-Ab­b­Vie med­ical chief suc­ceeds Brig­gs Mor­ri­son at ...

3 years ago
Peer Review
First page Previous page 364365366367368369370 Next page Last page
A service from the Financial Times